In the Indian pharmaceutical industry, there were 7 private equity deals announced in Q2 2023, worth a total value of $3.2bn, according to GlobalData’s Deals Database. The $2bn institutional buy-out (ibo) manipal health enterprises by Temasek Holdings (Private) was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity in India increased by 626% in Q2 2023 compared with the previous quarter’s total of $440.8m and rose by 378% as compared to Q2 2022. Related deal volume increased by 17% in Q2 2023 versus the previous quarter and was 17% higher than in Q2 2022.
The top-ranked financial advisors supporting these private equity deals in India in Q2 2023 were Avendus Capital; BDA Partners; Nine Rivers Capital Holdings with 1, 1, 1 deals respectively.
The top-ranked legal advisorss supporting these private equity deals in India Q2 2023 were AZB & Partners; J Sagar Associates; Jerome Merchant + Partners with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.